NASDAQ:SNGX - Soligenix Stock Price, Price Target & More

Get Started

$1.58 -0.01 (-0.63 %)

(As of 05/24/2018 04:00 PM ET)

Previous Close$1.59

Today's Range$1.55 - $1.60

52-Week Range$1.54 - $3.70

Volume52,812 shs

Average Volume34,514 shs

Market Capitalization$14.33 million

P/E RatioN/A

Dividend YieldN/A

Beta0.56

About Soligenix (NASDAQ:SNGX)

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SNGX

CUSIPN/A

Webwww.soligenix.com

Phone609-538-8200

Debt

Debt-to-Equity RatioN/A

Current Ratio2.16

Quick Ratio2.16

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.43 million

Price / Sales2.54

Cash FlowN/A

Price / CashN/A

Book Value$0.47 per share

Price / Book3.36

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-7,140,000.00

Net Margins-149.71%

Return on Equity-182.10%

Return on Assets-105.34%

Miscellaneous

Employees18

Outstanding Shares8,740,000

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Friday, May, 11th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.02. The biopharmaceutical company earned $1.10 million during the quarter. Soligenix had a negative net margin of 149.71% and a negative return on equity of 182.10%. View Soligenix's Earnings History.

When is Soligenix's next earnings date?

Soligenix is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Soligenix.

What price target have analysts set for SNGX?

2 equities research analysts have issued twelve-month price targets for Soligenix's shares. Their predictions range from $3.00 to $5.00. On average, they expect Soligenix's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Soligenix.

Who are some of Soligenix's key competitors?

Some companies that are related to Soligenix include KaloBios (HGEN), Oasmia Pharmaceutical (OASM), Alimera Sciences (ALIM), Versartis (VSAR), vTv Therapeutics (VTVT), Addex Pharmaceuticals (ADDXF), Evoke Pharma (EVOK), Zosano Pharma (ZSAN), Catabasis Pharmaceuticals (CATB), Imprimis Pharmaceuticals (IMMY), ProPhase Labs (PRPH), Celsion (CLSN), IntelGenx Technologies (IGXT), Q BioMed (QBIO) and Moleculin Biotech (MBRX).

Who are Soligenix's key executives?

Soligenix's management team includes the folowing people:

Dr. Christopher J. Schaber Ph.D., Chairman, CEO & Pres (Age 52)
Ms. Karen R. Krumeich, CFO, Sr. VP, & Corp. Sec. (Age 64)
Dr. Oreola Donini Ph.D., Chief Scientific Officer & Sr. VP (Age 46)
Dr. Richard C. Straube M.D., MSc., Chief Medical Officer & Sr. VP (Age 66)
Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs

Has Soligenix been receiving favorable news coverage?

Headlines about SNGX stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Soligenix earned a media sentiment score of 0.06 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.57.

How big of a company is Soligenix?

Soligenix has a market capitalization of $14.33 million and generates $5.43 million in revenue each year. Soligenix employs 18 workers across the globe.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

MarketBeat Community Rating for Soligenix (SNGX)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		151 (Vote Outperform)
Underperform Votes:		84 (Vote Underperform)
Total Votes:		235

MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Soligenix (NASDAQ:SNGX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Soligenix in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 153.16%. The high price target for SNGX is $5.00 and the low price target for SNGX is $3.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.50	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$4.00	$4.00	$3.85	$5.25
Price Target Upside:	153.16% upside	47.06% upside	73.42% upside	172.02% upside

Soligenix (NASDAQ:SNGX) Consensus Price Target History

Price Target History for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/11/2018	Maxim Group	Set Price Target	Buy	$5.00	Low
3/16/2018	HC Wainwright	Set Price Target	Hold	$3.00	Low
9/7/2016	Aegis	Initiated Coverage	Buy	$6.00	N/A

(Data available from 5/24/2016 forward)

Soligenix (NASDAQ:SNGX) Earnings History and Estimates Chart

Earnings by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2018	1	($0.28)	($0.28)	($0.28)
Q3 2018	1	($0.27)	($0.27)	($0.27)
Q4 2018	1	($0.27)	($0.27)	($0.27)

Soligenix (NASDAQ SNGX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/9/2018							N/A
5/11/2018	Q1 2018	($0.29)	($0.27)		$1.10 million	View	N/A
11/6/2017	Q3 2017	($0.3230)	($0.17)	$1.36 million	$1.82 million	View	N/A
8/11/2017	Q2 2017	($0.3230)	($0.41)	$1.43 million	$1.00 million	View	N/A
5/11/2017	Q1 2017	($0.30)	($0.32)		$1.30 million	View	N/A
3/27/2017	Q4 2016	($0.85)	($0.17)	$2.90 million	$1.70 million	View	N/A
11/10/2016	Q3 2016		($0.43)	$2.50 million	$3.00 million	View	N/A
8/11/2016	Q2 2016	($0.90)	($0.20)	$2.50 million	$3.16 million	View	N/A
5/12/2016	Q1 2016		($0.40)		$2.63 million	View	N/A
3/24/2016	Q1	($0.06)	($0.04)	$1.00 million	$2.97 million	View	N/A
11/12/2015	Q3 2015	($0.90)	($0.40)	$3.00 million	$3.90 million	View	N/A
8/12/2015		($0.10)	($0.15)	$1.00 million	$1.10 million	View	N/A
5/14/2015	Q1 2015	($1.00)	($0.70)	$1.50 million	$0.82 million	View	N/A
3/24/2015		($0.10)	($0.07)	$0.80 million	$1.93 million	View	N/A
11/10/2014		($0.09)	($0.08)	$1.51 million	$2.79 million	View	N/A
8/11/2014		($0.09)	($0.05)	$0.80 million	$1.40 million	View	N/A
5/12/2014		($0.09)	($0.08)	$0.80 million	$0.90 million	View	N/A
3/26/2014		($0.08)	$0.13	$0.50 million	$1.38 million	View	N/A
11/12/2013	Q3 2013	($0.90)	($0.90)	$0.80 million	$0.31 million	View	N/A
8/12/2013	Q2 2013	($1.30)	($1.70)	$0.80 million	$0.60 million	View	N/A
5/3/2013	Q1 2013		($1.00)		$0.90 million	View	N/A
2/26/2013	Q4 2012		($0.80)			View	N/A
11/14/2012	Q3 2012		($0.70)			View	N/A
8/10/2012	Q2 2012		($0.90)			View	N/A
5/14/2012	Q1 2012		($1.30)			View	N/A
3/27/2012	Q4 2011		($0.85)			View	N/A
11/14/2011	Q3 2011		$2.00			View	N/A
8/12/2011	Q2 2011	($2.00)	($2.00)			View	N/A
5/13/2011	Q1 2011	($2.00)	($2.00)			View	N/A
11/12/2010	Q3 2010	($2.00)	($2.00)			View	N/A
8/13/2010	Q2 2010	($2.00)	($2.00)			View	N/A
5/17/2010	Q1 2010		($2.00)			View	N/A
4/1/2010	Q4 2009		($2.00)			View	N/A
11/13/2009	Q3 2009		($2.00)			View	N/A
8/14/2009	Q2 2009		($2.00)			View	N/A
5/15/2009	Q1 2009		($2.00)			View	N/A
3/31/2009	Q4 2008		($0.60)			View	N/A
5/16/2008	Q1 2008		($2.00)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Soligenix (NASDAQ:SNGX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Soligenix (NASDAQ SNGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 13.74%

Insider Trading History for Soligenix (NASDAQ:SNGX)

Institutional Ownership by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ SNGX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/29/2017	Spa Essetifin	Insider	Buy	293,510	$2.12	$622,241.20
5/8/2017	Randal J Kirk	Major Shareholder	Sell	160,968	$3.12	$502,220.16
12/16/2016	Christopher J Schaber	CEO	Buy	15,804	$3.16	$49,940.64	25,095
12/16/2016	Marco Maria Brughera	Director	Buy	2,000	$3.16	$6,320.00	2,750
12/23/2015	Jerome B Zeldis	Director	Buy	2,500	$1.27	$3,175.00	69,166
12/22/2015	Christopher J Schaber	CEO	Buy	10,000	$1.29	$12,900.00	85,761
12/22/2014	Joseph Michael Warusz	CFO	Buy	8,265	$1.21	$10,000.65
6/25/2013	Christopher J Schaber	CEO	Buy	9,523	$1.05	$9,999.15
6/25/2013	Keith L Brownlie	Director	Buy	19,047	$1.05	$19,999.35

(Data available from 1/1/2013 forward)

Soligenix (NASDAQ SNGX) News Headlines

Source:

Date	Headline
	SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine finance.yahoo.com - May 23 at 5:40 PM
	Soligenix, Inc. (SNGX) Forecasted to Earn FY2018 Earnings of ($1.10) Per Share www.americanbankingnews.com - May 16 at 8:07 AM
	-$0.28 EPS Expected for Soligenix, Inc. (SNGX) This Quarter www.americanbankingnews.com - May 15 at 5:14 PM
	Zacks Investment Research Weighs in on Soligenix, Inc.'s Q2 2018 Earnings (SNGX) www.americanbankingnews.com - May 15 at 8:02 AM
	Soligenix (SNGX) Issues Earnings Results www.americanbankingnews.com - May 12 at 11:50 AM
	Soligenix (SNGX) Given a $5.00 Price Target at Maxim Group www.americanbankingnews.com - May 11 at 6:13 PM
	Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results finance.yahoo.com - May 11 at 8:18 AM
	Soligenix to Present at the NYC Oncology Investor Conference 2018 finance.yahoo.com - May 7 at 8:15 AM
	Soligenix (SNGX) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - May 2 at 6:12 PM
	Soligenix (SNGX) Set to Announce Earnings on Wednesday www.americanbankingnews.com - May 2 at 7:00 AM
	Soligenix (SNGX) Coverage Initiated by Analysts at HC Wainwright www.americanbankingnews.com - April 17 at 11:58 PM
	Soligenix (SNGX) Given a $4.00 Price Target at Maxim Group www.americanbankingnews.com - April 15 at 3:59 PM
	Soligenix (SNGX) Price Target Increased to $5.00 by Analysts at Maxim Group www.americanbankingnews.com - April 10 at 5:37 PM
	Soligenix (SNGX) Given a $11.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - April 10 at 5:02 PM
	Analysts Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million www.americanbankingnews.com - March 27 at 7:59 AM
	Soligenix (SNGX) Cut to Neutral at HC Wainwright www.americanbankingnews.com - March 26 at 10:58 AM
	Soligenix, Inc. (SNGX) Expected to Announce Earnings of -$0.32 Per Share www.americanbankingnews.com - March 25 at 8:48 AM
	Soligenix, Inc. (SNGX) Granted Orphan Drug Designation from European Commission for RiVax for Prevention of Ricin Poisoning www.streetinsider.com - March 23 at 8:15 AM
	28 Stocks Moving In Thursday's Mid-Day Session feeds.benzinga.com - March 22 at 2:31 PM
	Maxim Group Analysts Give Soligenix (SNGX) a $5.00 Price Target www.americanbankingnews.com - March 22 at 1:59 PM
	Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning finance.yahoo.com - March 22 at 8:21 AM
	Soligenix (SNGX) Given a $3.00 Price Target at HC Wainwright www.americanbankingnews.com - March 16 at 7:47 PM
	Soligenix (SNGX) Given a $5.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - March 15 at 5:46 PM
	Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results finance.yahoo.com - March 15 at 8:12 AM
	Zacks: Brokerages Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million www.americanbankingnews.com - March 10 at 10:13 AM
	Soligenix (SNGX) & Jazz Pharmaceuticals (JAZZ) Head-To-Head Contrast www.americanbankingnews.com - February 26 at 10:48 AM
	Financial Contrast: Trillium Therapeutics (TRIL) & Soligenix (SNGX) www.americanbankingnews.com - February 5 at 9:46 AM
	$1.58 Million in Sales Expected for Soligenix, Inc. (SNGX) This Quarter www.americanbankingnews.com - February 4 at 6:12 AM
	Zacks: Brokerages Anticipate Soligenix, Inc. (SNGX) to Announce -$0.32 EPS www.americanbankingnews.com - February 2 at 2:22 PM
	Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials www.prnewswire.com - January 25 at 8:02 AM
	Windtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head Survey www.americanbankingnews.com - January 18 at 11:18 AM
	Head-To-Head Comparison: Soligenix (SNGX) and Osiris Therapeutics (OSIR) www.americanbankingnews.com - January 13 at 3:30 AM
	Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis finance.yahoo.com - January 4 at 11:01 AM
	Maxim Group Reiterates "$5.00" Price Target for Soligenix (SNGX) www.americanbankingnews.com - January 3 at 8:00 PM
	Analysts Anticipate Soligenix Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million www.americanbankingnews.com - January 1 at 2:38 PM
	Zacks: Brokerages Expect Soligenix Inc. (SNGX) Will Post Earnings of -$0.32 Per Share www.americanbankingnews.com - December 30 at 1:16 PM
	Critical Contrast: SIGA Technologies (SIGA) & Soligenix (SNGX) www.americanbankingnews.com - December 28 at 7:56 PM
	Soligenix (SNGX) Stock Rating Reaffirmed by Maxim Group www.americanbankingnews.com - December 21 at 4:28 PM
	Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule finance.yahoo.com - December 21 at 3:46 PM
	Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule www.prnewswire.com - December 21 at 6:26 AM
	Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX) www.americanbankingnews.com - December 15 at 9:32 PM
	Soligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 Million www.americanbankingnews.com - December 15 at 2:30 PM
	Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately finance.yahoo.com - December 8 at 3:50 PM
	Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX) www.americanbankingnews.com - December 2 at 9:56 PM
	Soligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 Shares www.americanbankingnews.com - December 1 at 9:02 PM
	Soligenix (SNGX) and ContraFect (CFRX) Head-To-Head Contrast www.americanbankingnews.com - November 30 at 3:12 AM
	Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA finance.yahoo.com - November 27 at 4:13 PM
	$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter www.americanbankingnews.com - November 27 at 8:11 AM
	Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX) www.americanbankingnews.com - November 26 at 1:16 AM
	Critical Survey: Soligenix (SNGX) vs. TetraLogic Pharmaceuticals Corporation (TLOG) www.americanbankingnews.com - November 23 at 5:46 AM

Soligenix (NASDAQ:SNGX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Soligenix (NASDAQ:SNGX) Income Statement, Balance Sheet and Cash Flow Statement

Soligenix (NASDAQ SNGX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff